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Abstract:  
Exchanging and understanding scientific data and their context represents a significant barrier to advancing 
research, especially with respect to information siloing. Maintaining information provenance and providing data 
curation and quality control help overcome common concerns and barriers to the effective sharing of scientific 
data. To address these problems in and the unique challenges of multicellular systems, we assembled a panel 
composed of investigators from several disciplines to create the MultiCellular Data Standard (MultiCellDS) with 
a use-case driven development process. The standard includes (1) digital cell lines, which are analogous to 
traditional biological cell lines, to record metadata, cellular microenvironment, and cellular phenotype variables 
of a biological cell line, (2) digital snapshots to consistently record simulation, experimental, and clinical data 
for multicellular systems, and (3) collections that can logically group digital cell lines and snapshots. We have 
created a MultiCellular DataBase (MultiCellDB) to store digital snapshots and the 200+ digital cell lines we 
have generated. MultiCellDS, by having a fixed standard, enables discoverability, extensibility, maintainability, 
searchability, and sustainability of data, creating biological applicability and clinical utility that permits us to 
identify upcoming challenges to uplift biology and strategies and therapies for improving human health. 
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Introduction 
Over the last several years, medicine and biology have become increasingly multi-institutional and collabora-
tive2,11-15. By pooling their resources, research communities can accelerate scientific progress: larger research 
consortia can jointly recruit patients to clinical trials that might otherwise be underpowered, create datasets that 
are too expensive or complex for individual institutions to build, assemble multi-parameter measurements from 
instruments that are too expensive or specialized to host at any one institution, and integrate diverse sets of 
expertise12,14,16.  
 
Research communities further benefit by adopting centralized data repositories with standardized data ele-
ments20. Sharing data and insights is less efficient when communicating by direct member-to-member interac-
tions with non-standard data, and “insight siloing” often results30. Shared repositories can spread the cost of 
data archiving and maintenance, while data standards make it possible to jointly develop data analysis tools. 
When shared repositories are publicly available, they provide a gold standard dataset promoting scientific re-
producibility31 and the broader community can contribute further tools and secondary analyses that bring fresh 
expertise and insights14,32,33.  
 
Recently, a consortium of 12 cancer centres in the NCI-funded Physical Sciences in Oncology Network 
(PSON) performed the most comprehensive characterization of two breast cell lines to date (MCF-10A: a non-
tumorigenic line, and MDA-MB-231: an aggressive metastatic line)2. After agreeing to unified cell line sources, 
culturing protocols, and quality control procedures, the consortium measured the microenvironment-dependent 
phenotypes of the two cell lines from multiple functional points of view (e.g., cell morphology, birth rates, multi-
omics, genomic stability, mechanics, therapeutic resistance). This collaboration demonstrates that multi-institu-
tional teams can study a problem in greater depth than would be possible by individual laboratories, with better 
cross-lab quality control and reproducibility.  
 
However, this effort has not yet reached its full potential. As no standard exists for a systematic, standardized 
data representation, the measurements were shared in a collection of figures, spreadsheets, and documents, 
spread amongst individual and compressed files in websites34 and journal-hosted supplementary data2. This 
has left the data almost undiscoverable, difficult to adapt for simulation studies and other post-publication anal-
yses, and difficult to extend by community data contributions, in contrast to centralized repositories with stand-
ardized data elements (e.g., TCGA35). More broadly, multicellular systems biology is in need of an extensible, 
orderly data format for use in cross-lab and cross-disciplinary data exchange. Otherwise, phenotypic measure-
ments from multicellular experiments remain trapped in individual papers, and cannot readily be mined to un-
derstand the relationships between individual cell multi-omics, microenvironment-dependent cell phenotype, 
multicellular dynamics, and emergent disease processes that ultimately drive patient prognosis.  
 
In this paper, we introduce MultiCellDS (MultiCellular Data Standard): a community-developed standard to fun-
ctionally describe cell phenotypes with contextual information from the microenvironment. We describe the use 
case-driven development process, which refined the standard until it could successfully represent a library of 
over 200 digital cell lines (DCLs): a hierarchical, standardized yet extensible representation of a biological cell 
line’s phenotype in one or more microenvironmental contexts. Additional use cases from digital pathology and 
multicellular simulations drove the development of digital snapshots: a spatial record of the microenvironment, 
its cells, and their phenotypes at a single time. Collections allow digital snapshots and digital cell lines to be 
logically grouped, such as by time course (e.g., a single simulation) or study (e.g., all segmented pathology 
slides from a patient cohort). MultiCellDS data can include metadata to assist curation, particularly provenance 
(data source) when aggregating measurements from many laboratories. These standardized data elements—
especially when combined with a centralised repository—can unify experimental, simulation, and clinical work-
flows, which often share common image and data analysis tasks, serving as biological references. See Fig. 1.  
 
The MultiCellDS project is a framework for community-driven curation of biological measurements, with the 
goal to enable more rapid collaborative science, better quality, and enhanced reproducibility. Digital Cell Lines 
(DCLs) provide a standardized way of reporting what is currently known about context-dependent cell 
phenotypes and their variability, so that what is not known can be assessed and prioritized so as to determine 
the state of collective knowledge, identify the biggest gaps in that knowledge, and determine what 
technological advances are needed to obtain those measurements to fill in those gaps. Additionally, this project 
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better enables researchers to investigate the impact of intra- and inter-laboratory variability in cell culturing pro-
tocols on standardized phenotype measurements, develop standardized phenotype benchmarks and reference 
values, improve quality control, and contribute to better reproducibility and cross-laboratory meta-analyses of 
experimental findings. Together with a repository to collect and share standardized, high quality data and by 
adopting MultiCellDS, the community has the responsibility to use, query, add, and improve the data so we can 
determine which cell and tissue parameters are most predictive to cell, tissue, and disease behaviour and, via 
a truly systematic representation of biological knowledge, rationally prioritize research directions at national 
and global levels, and potentially obtain the best return for limited funding resources. By collecting multiscale, 
multicellular data into open, public repositories makes research more reproducible, lets scientists test new 
biological hypotheses and therapeutic strategies, and ultimately can lay the groundwork 
to improve human health.  
Results 
A multidisciplinary, multi-institutional team of computational modellers, biologists, clinicians, engineers, and 
data scientists met virtually and in person to create a standard for multicellular phenotype data via use case 
development. Thus, our results are both a data standard and a starting library of standardized data. (See 
Method and Supplementary Materials for further details.) We created three iteratively refined primary data 
types: a digital cell line (DCL), a digital snapshot, and a collections type. We summarize these data types and 
their development below; full details can be found in the Supplementary Materials and at MultiCellDS.org. 
Data type: Digital cell lines 
A digital cell line (DCL) is a consistent, hierarchical organization of quantitative phenotype data for a single bio-
logical cell line, including the microenvironmental context of the measurements (which further organizes the 
data) and essential metadata (“data about data” such as biological classification, curation, quality, and citation 
information; see below). Its phenotype data elements are organized by function (Table 1) to help systemize 
information, while allowing flexibility and extensibility through user-defined custom data elements. The stand-
ard was refined until we could successfully represent a phenotype measurements for a library of over 200 cell 
types, including patient-derived and “standard” cultured cancer cell lines, endothelial cells (to test the standard 
against mesenchymal cells), yeast (to test against non-mammalian, non-cancer lines), and bacteria (to ensure 
the standard could represent prokaryotic cell data). 
 
Each DCL has two main parts: cell line metadata and one or more phenotype datasets. Cell line metadata in-
clude information about the personnel who created and maintain a DCL, where the data came from, and other 
information. A phenotype dataset functionally organizes currently available cell phenotypic measurements in a 
specific (and annotated) microenvironmental context for the measurements (e.g. phenotype measurements in 
hypoxic conditions). See Table 1. 
 
To record the data, we use XML (eXtensible Markup Language), a hierarchical, structured ordering of data ele-
ments that can be tailored to a specific domain using XML Schemas36,37 and related tools. Additionally, the 
data can be stored in databases. XML is an ideal format for collaboratively developing MultiCellDS due to its 
human-editable format, the availability of many pre-existing software packages, the ecosystem of related tech-
nologies (e.g. XPATH38), and its widespread support across simulation and data analytics software.  
 
Recording the cell phenotype 
Cellular behaviour measurements are grouped hierarchically by function in the phenotype element. The main 
functional groups record parameters associated with the cell cycle (including phase information), cell death, 
mechanics, motility, adhesion, pharmacodynamics (denoted by PKPD to include pharmacokinetic drug 
metadata), transport processes of chemical entities, geometrical properties, and mass (see Table 1). The level 
of detail describing the cell cycle can vary with the experimental or clinical setup (e.g., clinical pathology often 
uses Ki-67 positive / negative status to quantify proliferation39, while experimental investigations often annotate 
cell cycle status as G0/G1 or S/G2/M (e.g., using FUCCI40). Thus, we allow multiple cell cycle representations in 
a phenotype dataset. PKPD describes the pharmacokinetic of a drug response (e.g., changes in cell prolifera-
tion or motility) and drug pharmacodynamics for individual drugs (at one or more dosages) or combinations of 
drugs. In the future, we plan to integrate the PKPD data elements with PharmML41. 
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Microenvironment: context for the phenotype 
A cell’s microenvironment provides the context for its phenotype by indicating the external properties of a cell, 
like the mechanical stress and levels of chemical substrates in the immediate vicinity of the cell. Cells often 
behave differently in different microenvironments. For example, the cell birth rate decreases and the mean time 
spent in G0/G1 can increase for some cell lines when oxygen is reduced from normoxic (21% O2) conditions to 
hypoxic (0.1% O2) conditions42,43. The microenvironmental context for a phenotype measurement set is critical, 
not only for comparing data across experiments and cell types, but also for building computational models6,44. 
This observational approach allows us to link microenvironment and phenotype data without fully determining 
subcellular mechanisms (e.g., metabolic pathways). Since the data for these microenvironmental measure-
ments can come from multiple instruments with different sampling resolutions, or even order-of-magnitude esti-
mates, we permit multiple domains in the microenvironment data element. The microenvironment data element 
defines one or more variables (e.g., extracellular oxygen concentration), annotates them against existing ontol-
ogies like Chemical Entities of Biological Interest (ChEBI)45, and then records the value of each variable. See 
the Supplementary Information for more details.  
Phenotype Dataset: connecting phenotype, context, and other scales 
Each phenotype element is combined with a microenvironment element to form a phenotype dataset (a tuple of 
elements). This allows mapping a cell line from a position in the microenvironment space (all possible combi-
nations of microenvironmental conditions) to a position in the phenotype space (the space of all possible phe-
notypes). We use keywords to denote differences between the phenotype datasets (e.g. different levels of oxy-
genation) to make searching between phenotype datasets easier. See the Supplementary Material for further 
examples. In the long term, we plan to assemble DCLs for many different phenotype datasets (breadth), with 
each phenotype dataset having as much multi-scale, multi-omics data as possible (depth). 
Measurement-level metadata 
Several metadata elements can be associated with any MultiCellDS measurement as XML attributes. The at-
tached metadata will deal with measurement variability (e.g., standard deviation), uncertainty (e.g., margin of 
error), units (if applicable), and type. We annotate units with the Ontology of Units of Measure (OM)46, which 
allows prefixing of units and multiplication and powers of units. Measurement type allows us to indicate 
whether a measurement is raw (straight off an instrument), direct (directly measured by a specialised instru-
ment), inferred (derived by fitting a mathematical model to raw or direct data), literature (extracted from pub-
lished data for the same cell type and measurement conditions), estimated (estimated to order-of-magnitude 
based upon published data for similar cells in similar conditions), or assumed (e.g., a mathematical simplifica-
tion). See the Supplementary Material for more details. 
Cell Line Metadata: information about the digital cell line 
These metadata record information about an overall DCL rather than about individual measurements. Each 
DCL has a unique identifier (using the standards developed at identifiers.org47) and versioning information to 
help reproducibility. We record information about the people involved with a DCL (Creator, Curator, Current 
Contact, and Last Modified By) using well-established ORCID48 elements. When measurements are mined 
from pre-existing studies, we record the source publications and analysis protocols. Next, we record biological 
or clinical information like what species, strain, and/or organ the cell came from, pathological or clinical classifi-
cation, and any other unique identifying information. See the Supplementary Material for further details. 
Provenance, Reproducibility, and Aggregated Citations 
DCLs can aggregate measurements from multiple sources, using interpretations and analyses from several 
contributors. Over time, community-driven improvements lead to increasingly complex provenance for DCLs. 
The review process (see Methods) determined that DCLs must track and properly annotate this history to en-
sure both reproducibility and correct attribution while encouraging data contributions from the community. 
DCLs track data origins, creators and curators, and analysis software / algorithms as metadata. This informa-
tion can be used to create an aggregated citation that properly includes this information. For example: 
 
“We used digital cell line CELL_LINE_NAME [R1,R2] version ## (MultiCellDB ##), created with 
data and contributions from [R3,R4-Rn].”  
 
Here, R1 is the publication that originally introduced the DCL, R2 is the publication that introduced the latest 
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version (if different from R1), MultiCellDB ## is a unique identifier in the MultiCellDB repository, R3 is the pre-
sent paper (to define the MultiCellDS data elements), and R4-Rn are publications for (1) the original data used 
to create the DCLs, (2) software and algorithms used to analyse the data, and (3) previous versions of the DCL 
between the original and current version. This form of citation emphasizes data contributors (R4-Rn), data cura-
tors (R1,R2), and analytics software developers (R4-Rn).  
Digital Cell Line Numbering and Versioning 
Each DCL is assigned a unique identifier to distinguish it from other DCLs, while allowing simple identification 
of related DCLs. See Fig. 2 for further details. We demonstrate the interplay of the branches and versions with 
curatorial control in Fig. 3, using concepts originating in version control software systems such as git49 that 
support forks, branches, and merges of projects with version tracking. 
 
Data type: Digital Snapshots 
DCLs record averaged cell phenotype measurements and microenvironmental context on a static basis. How-
ever, it is important to record spatial and dynamical information as well. Motivated by use cases arising from 
recording segmented pathology images and cancer single-time simulation outputs, we extended the data ele-
ments from DCLs to create digital snapshots: a digitized record of the spatial distribution and phenotypic state 
of all cells in a specified region at a single point in time, along with spatial microenvironmental measurements. 
Digital snapshots can be applied to experimental, clinical or computational data, and they can describe either 
individual cells, clusters of cells, or cell densities. The review panel iterated on these data elements until they 
could sufficiently describe data outputs for several classes of computational models50, including continuum mo-
dels28,29,51,52 cellular automata53,54, cellular Potts models55,56, agent-based models51,57, and vascular network 
models58,59. See recent reviews for definitions of these models51,57. The panel further iterated the data elements 
to ensure that digital snapshots could sufficiently represent segmented pathology data from clinical and experi-
mental samples17.  See Supplementary Material Human Overview for further details. 
Data type: Collections 
The digital snapshot uses cases also exposed the need for logically bundling related digital snapshots, such as 
all saved times in a single simulation experiment or a patient cohort. Thus, we created the collections data 
type, which can bundle any combination of DCLs, digital snapshots, or other collections. The groupings permit 
novel and unforeseen combinations to emerge as the community continues to develop ideas about how the 
data should be aggregated. For example, each simulation in a computational study can now be bundled as a 
collection of digital snapshots (a time course), along with the DCLs used in the simulation. These collections 
themselves could be bundled in a collection to more easily share and archive the paper’s data.  
Ontology definitions, software, and extensibility 
While the XML schemas specify the structure of MultiCellDS, we must also annotate the meaning of the Multi-
CellDS elements, allowing a consistent definition of individual terms. To that end, we generated an OWL (Web 
Ontology Language)60,61 ontology from the XML schemas, permitting a mapping of each element onto its onto-
logical counterpart. (See Box 1 to define these terms.) We extensively link to other ontologies (e.g. Gene On-
tology (GO)62,63, Cell Behavior Ontology (CBO)64, Phenotypic Quality Ontology (PATO)65, Ontology of Physics 
for Biology (OPB)66), as these expert-defined ontologies provide excellent, time-tested definitions. Whenever 
possible, we adopted definitions from these pre-existing ontologies. Where terms were non-existent or poorly 
suited to multicellular systems biology, we defined new terms; these are defined in the OWL files. We used 
CodeSynthesis’ XSD/e67 and PyXB68 to create APIs to read and write MultiCellDS from C++ and Python re-
spectively. We expanded the software to automatically generate OWL files from our XML schemas.  
 
We anticipate that advances in experimental and theoretical biology and clinical science will necessitate new, 
descriptive data elements. To encode such data in MultiCellDS without clashing with standards-compliant soft-
ware, custom data can be inserted within clearly delineated <custom> data elements anywhere in the data hi-
erarchy. This allows scientists to rapidly adapt MultiCellDS to their needs without the potential bottleneck of 
requiring a full standards committee review and approval of updates to the standard. The standards panel will 
regularly analyse the most prevalent custom data elements for inclusion in future releases of MultiCellDS. The 
use of these custom elements demonstrates how MultiCellDS can seamlessly adapt to the changing needs of 
the research community, and how draft data elements can eventually become part of the full standard.  
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Digital Cell Line and Snapshot Library: MultiCellular DataBase (MultiCellDB) 
We created a public repository, the MultiCellular DataBase (MultiCellDB), at http://MultiCellDS.org/MultiCellDB, 
in order to store the MultiCellDS files.  This repository provides web based access to digital cells lines.  The 
repository is based on the DERIVA scientific asset management system69.  MultiCellDB allows contributors to 
upload DCL files which are stored in their original form, as well as converted into an entity-relationship model 
for storage in a relational database.  The MultiCellDB interface provides a faceted search capability and allows 
users to search for cell line data by phenotype, measurement value, microenvironment, or metadata value. 
DERIVA provides a fine grain access control mechanism which allows data sets to be quarantined while they 
are being curated prior to public release. 
 
To help drive development of the standard, we developed a library of over 200 DCLs. While most of these 
DCLs are for human cancer, we worked to ensure that the standard could handle non-cancerous and non-epi-
thelial human cells (HUVECs), non-human mammalian cells (murine lymphoma), single celled eukaryotes (S. 
cerevisiae), and prokaryotes (S. aureus and E. coli). See Table 2 for a complete listing and an overview of how 
the standard evolved due to the development of the DCLs. 
 
While iterating on the digital snapshot standard, we recorded simulation data including: previously reported  
2D agent-based ductal carcinoma in situ (DCIS) simulation data6 an agent-based simulation of a 3D tumour 
spheroid using Chaste3,4, 3D continuum simulations of vascularized brain cancer7,8 and lymphoma28,29, and a 
2D simulation of vascularized tumour growth using BioFVM1. We also used digital snapshots to record nuclear 
morphometric properties on segmented H&E breast cancer pathology images17. Using the same data elements 
for experimental, clinical, and simulation data was a motivating factor for founding the MultiCellDS project, as it 
allows more direct comparison of simulation and clinical / experimental validation data, as well as more direct 
initialization of simulations and unified analysis platforms. 
Discussion 
The MultiCellDS Project has grown from a single lab’s motivation to an international community, with the com-
mon goal of tackling the fundamental problem of recording and sharing multicellular data. By creating a stand-
ardized multicellular data representation with appropriate metadata, the research community can proceed to 
build big data repositories that are truly multiscale—including measurements from the molecular, cellular, multi-
cellular, tissue, and whole-organism/patient scales. With a growing collection of standardized data, we can de-
velop an ecosystem of stronger, mutually compatible software tools to quantitate and analyse data, devise new 
theories and predictions, and ultimately yield new discoveries that drive science and medicine.  
 
Learning from notable prior efforts70-72 (see Methods as well), we focused on the core problem of representing 
and structuring data, rather than annotating mathematical models. To accelerate development, we adopted a 
“startup” development model with a small core team responsible for leading development, an invited multidisci-
plinary review panel to review, refine, and test the standard, and frequent engagement with the broader scien-
tific community through public talks, conferences, and social media outreach. We employed a use case-based 
development cycle (choosing test problems and brainstorm solutions; discussing the prototype data elements; 
testing and refining until the tests succeed) in multiple rounds. In Round 1, we worked on describing microenvi-
ronment-dependent cell phenotype and cell line metadata. Round 2 focused on describing simulation and seg-
mented pathology data, while Round 3 (ongoing) worked to describe clinical outcome metadata and collections 
of data. Where possible, we leveraged existing ontologies and standards where well-developed data elements 
existed; we developed new data elements or extended standards when necessary. See Supplementary Mate-
rial Timeline for additional information.  
 
MultiCellDS’ three main data types, digital cell lines (DCLs), digital snapshots, and collections, respectively al-
low a broad characterization of cell behaviour across many microenvironmental conditions, record spatial infor-
mation (individual cells or cellular populations, distribution of microenvironmental substrates) at a single time, 
record key metadata, and organize the former two types into logical groupings (e.g., variants of MCF-7, time 
series data, data replicates). By utilizing the same data, we facilitate better exchange and comparison of data 
between quantitative modellers, data scientists, experimentalists, and clinicians. The use case-driven develop-
ment created a library of over 200 DCLs, spanning prokaryotes and eukaryotes, epithelial and stromal cells, 
and patient-derived and “standard” cell lines. These are stored in a public repository, MultiCellDB, at http://Mul-
tiCellDS.org/MultiCellDB. The work also generated a collection of digitized, segmented, and spatially annotated 
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breast pathology data (as digital snapshots) and simulation outputs (which can be used to benchmark future 
models). The hierarchical nature of MultiCellDS, while challenging to traditional database methods as the data 
are not flat (easily represented in a two-dimensional table), is critical to maintain its organization, searchability, 
and extensibility.  
 
Having agreed on a data standard with an initial public data repository, we will now turn our focus to broader 
community involvement, to encourage data and software tool contributions as well as refinements to the stand-
ard. This is already partly accomplished through aggregated citations: contributors are credited for contributing 
new measurements or improved analyses, and original sources are always attributed. The momentum of  the 
effort may also incentivize participation: as more data and more software tools become available using the 
standard, new developers will have incentive to also adopt the standard to make use of those data and tools. 
However, at this early stage, we envision that additional incentives may be needed, such as data hackathons 
with prizes (to encourage creation of tools), partnerships with granting agencies and journals (to encourage 
publication of supplementary data in standardized formats), and collaborations with instrument makers (to ena-
ble simple, direct writing of standards-compliant data). Moreover, the repositories and software need to be 
searchable, flexible, and easy to use, to prevent user frustration that can ultimately doom any emerging tech-
nology. The MultiCellDS community must involve user feedback and experts in human-computer interaction 
when developing and refining tools. The built-in support for custom data elements should ensure sufficient flex-
ibility, and the biologic functional-driven hierarchy of data elements helps to ensure that the data are searcha-
ble.  
 
As we conclude the technical challenges of writing and aggregating data into shared digital cell lines, we face 
new challenges in curation and quality control. How do we assess the quality of a new measurement9? When 
should a new measurement replace an existing measurement? Who is responsible for and granted authority to 
make such decisions? These open questions can be addressed by forming community standards for cura-
tion—a natural evolution of the current standards review panel. While prior efforts exist for other biological do-
mains (e.g. the International Society for Biocuration), the multicellular community must create curatorial data 
requirements suited to its own domain. As this important work progresses, the community can collectively im-
plement heuristics to help pre-screen new data, based on prior annotated knowledge. (e.g. “Cell radius for hu-
man breast cancer cells should be between 5-15 µm; raise a warning flag and any values outside that range.”) 
In the future, machine learning could not only flag bad measurements but identify typical causes (e.g., culturing 
without a key growth factor) and suggest solutions, thus improving experimental workflows.   
 
In the future, we will continue developing the MultiCellDS data elements and metadata to sufficiently record 
data from emerging clinical trials and machine learning experiments in digital pathology and will extend the 
standard to HDF573 (a widely-supported compressible hierarchical data format in the physical sciences). Multi-
CellDS can currently describe cell phenotype broadly across many microenvironmental conditions. Future work 
will add depth by integrating subcellular scales (e.g., metabolomics, receptor trafficking, and other “omics”) into 
the phenotype datasets, leveraging established standards such as SBML at those scales. Standardizations for 
the dynamics of pharmacodynamics and pharmacokinetics are needed to truly characterize high-content drug 
screening data and predict clinical response. We will work closely with the PharmML team to develop these 
data elements while harmonizing data elements across PharmML, SBML, and other standards. We will also 
work with leading open source computational modelling projects (particularly Chaste, CompuCell3D55, 
PhysiCell74, and TiSim75) to build software cross-compatibility by supporting the MultiCellDS data format; in-
deed, this work has already begun.   
 
The new MultiCellDS standard and repository represent a start to sharing well-structured, machine-readable 
multicellular data. Now that we have tackled the issues of how to consistently record and structure data span-
ning many sources and types, it is time to work on building larger databases of multiscale, multicellular data, as 
has recently been highlighted by USA’s Vice President Biden’s “Cancer Moonshot” project76 and countless ad-
vocates for big data, open science, and reproducibility. With large repositories of consistently structured data, 
we can apply machine learning, mechanistic modelling, and other quantitative techniques to the big data to 
start answering big and significant questions: What is the state of our collective knowledge today? Where are 
the biggest gaps? Which cell and tissue parameters are most predictive to cell, tissue, and disease behaviour? 
And if those measurements are currently lacking, what technological advances are needed to obtain them? 
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Through a truly systematic representation of biological knowledge, we can rationally prioritize research direc-
tions at national and global levels, and potentially get the best return for limited funding resources.  
 
MultiCellDS gets us off the ground by providing a consistent means to record multicellular data. The repository 
helps to collect and share standardized data. The community now has the opportunity as well as the responsi-
bility to make use of the data: to contribute more data; to mine the data for subtle patterns that drive new hy-
potheses; to test new hypotheses in computational, experimental, and clinical models; and to unlock new 
knowledge that drives scientific progress and yields new therapies and strategies to improve human health.  
Method 
Originating as MultiCellXML (MultiCellular eXtensible Markup Language)6, MultiCellDS grew and was impacted 
by other standardization efforts. MultiCellDS focused on satisfying unmet needs in model-independent data 
descriptions—rather than model representation—to facilitate interchange of data between computational mod-
ellers, experimental biologists, and clinicians. We adopted a “startup” organizational structure to promote faster 
development of the data standard. We employed a use case-driven development process to iteratively assess 
and refine the standard while ensuring that it could succeed at its primary tasks of (1) representing and sharing 
microenvironment-dependent cell phenotype data while preserving provenance, and (2) sharing standardized, 
model-independent spatial multicellular state data from many types of simulations and segmented pathology 
images.  
Lessons from prior standardization efforts 
To date, there have been successful instances of shared biological data repositories in molecular biology (e.g., 
TCGA35) and clinical medicine (e.g., some clinical trial databases77), where the data are relatively homogenous 
(many records with identical data elements) and flat (non-hierarchical). However, at the intermediate scales—
cell phenotype and multicellular organization—efforts have been less successful. Encyclopaedias such as the 
Cancer Cell Line Encyclopedia (CCLE)78 have successfully collected useful molecular information, but have 
generally lacked phenotypic and multicellular data; the mapping from genotype to phenotype is not always 
straightforward, and demonstrating how cells interact with one another requires an understanding beyond sin-
gle cells in isolation. Moreover, encyclopaedias have a tendency towards recording static data, discouraging 
active community contributions of improved measurements and analyses.  
 
In a key advance towards community-driven databases, BioNumbers7 allows much more active user contribu-
tions and provides a generalized search engine. However, the data are not organized by cell type, there is no 
adaptable, hierarchical organization to help searches and comparisons by function, and there is no consistent 
reporting of microenvironmental metadata (e.g., oxygenation conditions, and growth medium used), even as 
these are known to impact cell phenotype42,43,79. Earlier data standards have similarly worked to describe cellu-
lar data (e.g., The Systems Biology Markup Language (SBML)70,71, CellML72), but they have largely focused on 
representing individual mathematical or computational models and their corresponding parameter values, ra-
ther than annotating model-independent cell phenotype. Moreover, these well-established standards have fo-
cused primarily on subcellular and cell-scale properties; only recently has SBML begun drafting specifications 
to represent multicellular models with its Dynamic and Spatial Processes packages, but the complexity of rep-
resenting a wide variety of mathematical models has necessitated a long-term development process (e.g. 
SBML’s history80).   
 
The development of ontologies (e.g. GO62,63) has helped improve recording results, but we focus on a key dif-
ference between an ontology and a data standard: ontologies are like dictionaries by defining terms, and data 
standards are like grammars that give a predictable structure to the terms. Both are necessary to communicate 
data fully and should drive the development of one another. The Cell Behavior Ontology (CBO)64 has helped 
steer the development of MultiCellDS, and we have submitted improvements to the CBO. 
 
We chose the MultiCellDS organization model and development process based upon the lessons learned from 
these earlier projects. We focused on representing model-independent phenotype data to avoid the inherent 
complexity of representing all current and possible future mathematical models. This had the additional benefit 
of allowing the same data elements to represent experimental, clinical, or computational data. We iteratively 
tested and refined the emerging standard against a series of use cases stemming from simulation, experi-
mental, and clinical science. This made development more concrete while ensuring that the final standard 
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achieved its design goals. We adopted a “startup” organizational model, where a core group of “invested” par-
ticipants (based at the University of Southern California) took responsibility for drafting and developing the 
standard. The core group recruited a multidisciplinary review panel of leading biologists, clinicians, modellers, 
and data scientists, each stakeholders in their own domain to refine and improve the draft standard while com-
pleting the use cases. Public presentations at scientific meetings and social media interactions were used to 
solicit and incorporate feedback from the broader scientific community.  
Creating the MultiCellDS standard 
MultiCellDS originated as a way to save agent-based simulation data in a model of DCIS of the breast6. Key-
note talks and discussions with modellers and experimentalists at the NCI-funded Physical Sciences in Oncol-
ogy Network (PS-ON) 2013 annual meeting81 found the need to standardize data at the multicellular scale, for 
improved sharing of phenotype measurements, experimental data, and simulation outputs. To drive rapid pro-
gress towards a working standard, we used a two-stage strategy: in the first year of the project, we assembled 
a core team at USC to integrate early consensus opinions from the 2013 PS-ON annual meeting into the pre-
ceding MultiCellXML draft specification. By the end of this year, we had developed a working draft standard for 
DCLs and digital snapshots.  
 
In Year 2, we expanded the development process to a select multidisciplinary panel of computational model-
lers, clinicians, data scientists, software developers, and biologists. Panel members were recruited from the 
PS-ON and the broader scientific and medical communities. Social media engagement and public presenta-
tions were used to recruit further review panellists. The full panel membership list is given in the Supplemen-
tary Material. The review was organized into three rounds: Round 1 (completed) focused on DCLs, and 
Round 2 (completed) focused on digital snapshots for simulation and experimental data. Round 3 (in progress) 
is focused on clinical, pathologic, and radiologic data elements. The core team and review panel determined 
that the data standard should be released in parts, rather than waiting for the completion of all three rounds. 
This was to give faster utility, help accelerate adoption, and ease the cost and effort of software implementa-
tion, by allowing parts of the standard to be implemented as they are completed.  
 
Each review round consisted of three phases. The first phase (“brainstorming”) used one-on-one interactions 
with panel members and the broader public through video conferencing and seminar talks to explore and pro-
pose data elements and their hierarchical relationships. XML schema files were maintained throughout this 
process to fully capture the definitions and allowed relationships in MultiCellDS XML files. The second phase 
(“formal review”) conducted a series of “town hall” style videoconferences with the review panel, to allow frank 
discussion of the elements and solicit feedback. The core group introduced refinements to the XML schema 
files between each town hall meeting. The third phase (“test-based refinements”) tested the new data elements 
against specific task(s) by the review panel members, to expose bugs and omissions in the standard. Refine-
ments were made to the schemas until the tests could be successfully completed. See the timeline in the Sup-
plementary Materials.  
 
The Round 1 tests used clinical, experimental, and literature data to create DCLs for mammalian cells (cancer, 
stromal, and other types), non-mammalian cells (yeast), and prokaryotic cells (S. aureus and E. coli), with vary-
ing levels of detail (see Results and Supplementary Material.) Round 2 tests focused on representing simu-
lation outputs for many discrete3,4,6,53-56,82-84 and continuum28,51,85-87 computational models and segmented nu-
clei in clinical pathology data. Round 3 tests will represent more general clinical pathology data.  
Use case: Building a library of digital cell lines 
We have created DCLs for a wide variety of cell types, with the largest number of DCLs coming from (1) indi-
vidual patients in cancer studies and (2) many cancer types from data provided by ATCC to the PS-ON5. We 
also created DCLs for Human Umbilical Vein Endothelial Cells (HUVECs), lymphoma, yeast and bacteria. We 
put these DCLs into an online searchable repository (MultiCellDB). We have found that the hierarchical nature 
of the DCLs was challenging to traditional database methods as DCL data are not flat (easily representable in 
a two dimensional table); this hierarchical nature is critical to maintain the organization, searchability, and ex-
tensibility of MultiCellDS. Each collection of DCLs presented unique annotation challenges, thus driving refine-
ments in the data standard.   
Systemizing data for previous PS-ON investigation 
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Earlier work2 measured a wide variety of cellular properties of MCF-10A and MDA-MB-231 cells. However, ob-
taining numerical information from this paper presented a set of challenges, since the data are not easily ac-
cessible. Data values are presented in plots, sometimes in the text of the paper or supplementary material, 
sometimes in a Word file contained in a compressed file stored on an unreferenced Wiki, and sometimes in 
Word documents that are not available online in any form at all (except by request from individual co-authors). 
We also encountered inconsistent formats and missing growth parameters. While presenting data in these vari-
ous formats can speed up initial data exchange between collaborators (at the level of files, tables, and plots), it 
does not contribute to detailed information exchange (e.g., direct comparison and combination of measure-
ments between groups), nor facilitate quantitative communication between computational models, other soft-
ware packages, and databases. When creating the MCF-10A and MDA-MB-231 DCLs, we systemized the re-
ported data and collected missing primary information from the authors to complete the DCLs. This systemati-
zation of the data thus continues the impetus for the original study. To successfully complete this set of DCLs, 
we created “dimensions” of data to record additional results. Often, a parameter is represented by a single 
value, but will be representative of a larger collection of non-temporal data points; for example, Young’s modu-
lus measurements as the slopes of linear fits to multiple indentation measurements. We record this larger col-
lection to retain the original knowledge and provide better confidence in future results; see Anscombe’s Quar-
tet88. 
Creating digital cell lines from experimental protocol information 
The Physical Sciences in Oncology Bioresource Core Facility offers cell line information and standard operat-
ing procedures (SOPs) for 38 human cell lines derived from 7 organs, as freely-available PDF files5. We ex-
tracted a growth curve (as an image) from the PDF documentation for each cell line, processed the image in 
MATLAB to extract the cell counts and standard deviations at several time points, and performed a nonlinear 
least squares fit of the extracted data to exponential and logistic growth models (see the Supplementary Mate-
rials) to extract cell birth rate parameters. (The software to reproduce this work can be found at https://source-
forge.net/projects/multicellds.) We also extracted metadata from the SOPs, and combined these with the cell 
birth rate parameters to create 38 minimal DCLs which can later be extended by the broader community, anal-
ogously to Wikipedia “stubs”89. Work on this early collection of DCLs (with its variety of cancer types and cellu-
lar origins) exposed the need for detailed biological cell line metadata elements. We introduced metadata re-
lated to a cell’s origin, so that we could distinguish between the different types of cancers (e.g. breast cancer 
vs. colon cancer). This logically extended to have other subelements, e.g. disease or species/organisms. 
Two collections of patient-derived digital cancer cell lines 
Patient cohorts permit studying the variability of cell phenotype, albeit over a larger range of genetic variability. 
The addition of clinical data allows a systematic way of relating various phenotype measurements to clinical 
outcomes. We refined the MultiCellDS draft standard to record phenotype measurements for two collections of 
patient cell lines: glioblastoma multiforme (GBM), based upon radiology, clinical outcome, and limited pathol-
ogy data10, and DCIS of the breast, based upon morphometric and other pathology-based measurements18. 
The GBM collection includes 39 patients with motility data and an additional 133 patients with partial data, but 
not as complete as the other patients10. To successfully create the GBM DCLs, we introduced (de-identified) 
patient- and disease-focused metadata to the standard. For the DCIS collection, we created 17 patient-derived 
DCLs, using an updated calibration protocol which improved upon previous methods6; see the Supplementary 
Materials. To create these DCLs, we required new metadata elements to describe the patient clinical staging 
information, as well as organism, organ, and tissue identifying elements. 
Other digital cell lines 
The lymphoma DCLs stem from two papers28,29, and include geometrical properties, PKPD responses, and cell 
cycle data. To ensure that both eukaryotic and prokaryotic cells can be successfully represented, we created 
DCLs for Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli) bacteria to record proliferation, size, 
and mechanics data26,27. Future MultiCellDS releases will include new data elements for bacterial biofilms, as 
these properties are known to impact cell proliferation, death, and response to antibiotics and other environ-
mental stressors90,91. Human Umbilical Vein Endothelial Cells (HUVECs) have several different behavioural 
“states”: as tip, stalk, and phalanx cells22, and we denote the different phenotype datasets using keywords.  
The HUVEC DCLs recorded these proliferation parameters, transport processes, motility, size and motility data 
elements based previous work16,21,92,93. Data reported in nine different papers had parameters that could have 
potentially been used for DCLs21,92,94-107; however, these papers reported qualitative data (e.g., an environmen-
tal factor increases motility, but with unspecified magnitude) or relative quantitative data (e.g., a proliferation 
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rate may double relative to control, but with no scale reported). This makes it difficult to combine and compare 
data from multiple sources. 
 
The yeast Saccharomyces cerevisiae is a model organism for eukaryotic cells and cell cycling. Thus yeast are 
an important use case for DCLs, for building predictive mathematical models as well as translating observed 
microscopic behaviour to macroscopic population level behaviour. Because yeast can be grown in liquid or 
solid media, this DCL details the solid media preparation23. The replicative behaviour of yeast has been quanti-
fied in many studies24. We note that the cell cycle of yeast is different for cells in their first division, which have 
an extended G1 phase. The replicative life span of yeast is thought to depend on the number of cell divisions 
rather than a specific time span; the average life span is around 25 divisions25. Yeast have cell walls rather 
than cell membranes – as in human cells – and the mechanical properties of these walls have been docu-
mented108. Finally, yeast cells reproduce through a budding mechanism where newly born daughter cells do 
not inherit the replicative age of the mother. Thus, the yeast use case required us to introduce new data ele-
ments to record a generation count that increases with each division.  
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Supplementary material: 
The MultiCellDS project website is hosted at http://MultiCellDS.org. A list of MultiCellDB portals, including the 
MultiCellDB reference repository, can be found at http://portals.MultiCellDS.org.  
1. User-focused overview of the data standard. [https://dx.doi.org/10.6084/m9.figshare.4269254.v1].  
2. List of supported cell cycle representations. [https://dx.doi.org/10.6084/m9.figshare.4269263.v1] 
3. Computer-generated documentation on the full standard, based upon the XML schema. 
[https://dx.doi.org/10.6084/m9.figshare.4269269]. 
4. The XML schema that official encodes the data standard. 
[https://dx.doi.org/10.6084/m9.figshare.4269272.v1 and 
https://dx.doi.org/10.6084/m9.figshare.4269275].  
5. OWL ontology. [http://MultiCellDS.org/ont/multicellds.owl]. 
6. A protocol to transform DCIS pathology data into patient-derived digital cell lines. 
[https://dx.doi.org/10.6084/m9.figshare.4269248.v1]. 
7. Mathematical models used in the Chaste demonstration of MultiCellDS digital snapshots 
[https://dx.doi.org/10.6084/m9.figshare.4272242]. 
8. Matlab script used to help create ATCC-based digital cell lines  
[https://sourceforge.net/projects/multicellds/files/Tools/ATCC_to_digital_cell_lines/]  
9. Community norms for curation, versioning, and new data elements 
[https://dx.doi.org/10.6084/m9.figshare.4272374.v1].  
10. Current MultiCellDS invited reviewers. [http://MultiCellDS.org/Team.php#review_panel] 
11. MultiCellDS invited reviewer (rounds 1-3, through Nov. 2016). 
[https://dx.doi.org/10.6084/m9.figshare.4272197] 
 
All MultiCellDS documentation can be found at http://MultiCellDS.org/Documentation.php.  
 
A list of MultiCellDS-compatible software is maintained at http://software.MultiCellDS.org.  
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FIGURES AND TABLES 
 
 
  
 
Fig. 1: Experimental, computational, and clinical workflows all share data/image analysis (green), quantitative / analytical 
(blue), and biological interpretive (red) tasks. Adopting standardized data representations, along with shared data 
repositories, allows better integration of these workflows: standards-compliant image processing, data analysis, and machine 
learning software can be reused across the workflows, and computational, experimental, and clinical models can be more 
readily compared and cross-validated.  
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Fig 2. Systematic version-based numbering: Each number has four parts: Line.Variant.Branch.Version. A Line repre-
sents a distinct type of cells, e.g. MCF-7. Each Variant represents a (sub-)line associated with a particular organization or 
group that may have customized the cell line, e.g. ATCC or an investigator’s group. Each list of variants is independent of 
the parent line. The 0th variant represents the collective behaviour aggregated over all variants. Each Branch represents a 
particular set of (curated or uncurated) measurements. For example, one branch could have curated Young’s Modulus 
measurements and another branch could have uncurated cell cycle phase durations. The 0th branch is the curated version 
with the most data included, pending any potential conflicts in the data between various branches. The Version represents 
the improvement (increase in quantity or quality) of the data in the DCL, thus recording the history and evolution of the 
data. By having lines, variants, branches, and versions of DCLs, we can record new data without impacting any pre-
existing DCLs. In this example, the red line shows DCL 1.1.1.2 for the MCF-10A line with the ATCC variant with Young’s 
Modulus measurements and the second version of the data. 
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Fig 3. Interaction of branches and versions (example). Initially, a flow cytometry group contributes data in a new branch 
(#1) and merges it into the master branch (#0). A previously designated master branch curator accepts the merge. Later, the 
flow cytometry group mistakenly updates its branch (#1) with faulty data; the curator rejects the merge to the master branch. 
Meanwhile, a cell mechanics group forks (duplicates) the master branch to create a new mechanics branch (#2), adds their 
data to the new branch, and merges this data into the master branch. Because the master branch curator cannot evaluate 
the mechanics data and it does not conflict with any pre-existing data, the data are automatically accepted into the master 
branch. The flow cytometry group collects new data to revise their branch (#1), and the master branch curator approves the 
merge. Lastly, the mechanics group seeks the newly curated flow cytometry data and merges the master branch into their 
mechanics branch (#2). Each successful commit or merge results in a new version of the DCL. In terms of access, all data 
should be publically available, unless a private branch has been created (forking). We purposely limit describing any policies 
to let each community develop their own standards. See Supplementary Material: Norms for MultiCellDS.  
Legend: Solid circles are commits, green solid upward diagonal lines are merges, blue solid downward diagonal lines are 
pulls, unfilled circles are conflicts and merges, and curved dashed lines are the introduction of additional data. 
Main elements in a digital cell line (DCL) 
Metadata: 
 
Biological cell line details, data sources, curation and 
contact details, versioning, and citation information 
Phenotype dataset: 
○ Microenvironment 
○ Phenotype 
A set of measurements in a microenvironmental 
context 
○ Details on the microenvironmental (ME) conditions 
○ Phenotype measurements in this ME context 
 
Key functional elements in a phenotype 
Functional group Typical data elements 
cell cycle 
cell death 
mechanics 
adhesion 
motility 
transport 
PKPD 
geometrical 
properties 
mass 
cell parts 
Duration and variability of cell cycle phases, death 
rates 
Duration, water loss rate, degradation rate 
parameters 
Young’s modulus, maximum stretching deformation 
Surface adhesion receptors 
Maximum cell velocity, correlation with chemokines 
Substrate import and export rates 
Cell birth and death response to a specific drug dose 
Cell volume, fluid fraction 
Cell biomass 
Young’s modulus in the nucleus 
Table 1. Key functional parts of a digital cell line (top) and phenotype (bottom). 
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Collections of digital cell lines 
Collection Number Description New or Improved Elements  
PSON 2 Very detailed MCF-10A and MDA-MB-231 human breast cell lines 
based upon PSON work.2  
“Dimensions” of results, e.g. force 
vs. indentation amount 
ATCC 38 cancer cell lines built from publicly-available ATCC data sheets5 None 
GBM 
 
39 (133) glioblastoma multiforme (aggressive brain cancer) based on 
patient data10. 39 detailed lines, 133 additional partial lines. 
Patient and Disease Elements 
DCIS 17 ductal carcinoma in situ of the breast, built from previously 
published patient pathology data18 and modest extensions of 
earlier parameter estimation protocols6,19. 
Patient and Disease Elements 
endothelial 1 endothelial cell lines, built from prior literature16,21 for HUVECs None 
yeast 1 species based on previously-published data22-25 (first non-
mammalian digital cell line) 
Generation number 
bacteria 2 species based on previously-published data26,27  (first non-
eukaryotic digital cell lines) 
None 
lymphoma 2 murine lymphoma lines based upon previously published 
experimental/simulation studies28,29 
None 
Table 2. Summary of digital cell lines in the library. 
Collections of digital snapshots 
Collection Description New or Improved Elements  
BioFVM 3-D spatial agent-based simulation of tumor spheroid 
response to a chemotherapy to test multi-substrate 
representation1 
Vectors of substrates 
Chaste_ABM 3-D tumor spheroid simulation3,4 Additional cell cycle models 
DCIS_ABM 
 
previously published agent-based model outputs, translated 
to prototype MultiCellXML to current standard6 
 
GBM outputs from a continuum (cell density) simulation of 
glioblastoma multiforme7,8. 
Clinical annotations 
mouse_liver 3-D segmented liver pathology9,10 Refinements to vascular elements, 
representation of pixel-level data 
BC_pathology nuclear segmentation and quantitation applied to previously 
published breast cancer pathology images17 
Clinical annotations 
Table 3. Summary of digital snapshots in the library. 
data element a specific measurement (e.g., the radius of a cell nucleus); the smallest unit of data in MultiCellDS 
XML An extensible markup language (similar to HTML used for webpages), which can order data element 
hierarchically to match their relationships in biology 
XML schema A template for XML data, which describes the allowed data elements and how they can be arranged  
metadata Data about the data: extra information such as units, scale, uncertainty, or provenance 
ontology A controlled dictionary of allowed terms  
OWL A standardized ontology file, in the “web ontology language” format 
provenance The history of who created data, who revised it, who maintains it, and where it is published. 
MultiCellDS multicellular data standard 
MultiCellDB  MultiCellDS database 
MultiCellXML MultiCellDS data, written in an XML format 
phenotype dataset A collection of cell phenotype and other measurements, in a single microenvironmental context 
digital cell line A collection of phenotype datasets and key metadata for a single biological cell line or type 
digital snapshot A readout of all cells, their phenotypes, and the microenvironment at a single time 
collection A logical grouping of one or more digital cell lines, digital snapshots, collections, or a combination of these 
 
Box 1. Summary of digital snapshots in the library. 
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